This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ALLHAT was a randomized phase 3 trial with a primary purpose of prevention. Its registered title describes an investigation of antihypertensive and lipid-lowering treatment to prevent heart attack. The registry identifies cardiovascular and related conditions including hypertension, coronary disease, heart disease, myocardial infarction, myocardial ischemia, heart failure, diabetes mellitus, and hypercholesterolemia.
| Feature | ALLHAT |
|---|---|
| Official title | Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) |
| Phase | Phase 3 |
| Status | Completed |
| Allocation | Randomized |
| Primary purpose | Prevention |
| Start date | 1993-08 |
| Primary completion date | 2002-03 |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| ClinicalTrials.gov identifier | NCT00000542 |
2. Clinical Question
The registry identifies ALLHAT as a randomized phase 3 prevention trial of antihypertensive and lipid-lowering treatment intended to address heart-attack prevention. The listed conditions place the study within a broad cardiovascular population involving hypertension, coronary disease, heart disease, myocardial infarction, myocardial ischemia, heart failure, diabetes mellitus, and hypercholesterolemia.
Population
The registry associates the trial with cardiovascular and metabolic conditions including cardiovascular diseases, coronary disease, diabetes mellitus, heart diseases, hypercholesterolemia, hypertension, myocardial infarction, myocardial ischemia, and heart failure.
Intervention domain
The intervention list includes ACE inhibitors, amlodipine, lisinopril, doxazosin, chlorthalidone, pravastatin, and a fat-restricted diet.
Primary purpose
The registry classifies the primary purpose as PREVENTION.
Primary question
The registry title frames the study around antihypertensive and lipid-lowering treatment in relation to prevention of heart attack.
3. Trial Design
Intervention structure reported by the registry
Drug interventions
- Inhibitors, ACE
- Amlodipine
- Lisinopril
- Doxazosin
- Chlorthalidone
Additional interventions
- Pravastatin
- Diet, fat-restricted
The registry's intervention list identifies the agents and behavioral intervention but does not, in the information available here, specify treatment doses, treatment durations, individual randomization ratios, or the precise assignment structure linking each intervention to particular study arms.
4. Endpoints
The ClinicalTrials.gov record does not report any registered primary endpoints in the information available for this trial. Consequently, specific endpoint definitions and time frames are not reported in the registry record summarized here.
| Endpoint information | Registry status |
|---|---|
| Registered primary endpoints | None reported in the ClinicalTrials.gov record |
| Endpoint definitions | Not reported in the registry information available here |
| Endpoint time frames | Not reported in the registry information available here |
| Posted statistical analyses | None reported in the ClinicalTrials.gov record |
5. Statistical Methodology
The ClinicalTrials.gov record identifies ALLHAT as randomized, but it does not report a statistical analysis plan or posted statistical analyses in the information available here. The registry also does not provide registered primary endpoint definitions or analysis time frames.
What randomization contributes
Randomization creates the fundamental comparison structure for a controlled clinical trial. If treatment assignments are made according to a randomized allocation mechanism, baseline prognostic factors—both measured and unmeasured—can be balanced in expectation across treatment groups. This is the principal statistical reason randomized trials can support causal comparisons more directly than observational studies.
The exact form of the treatment effect depends on the endpoint. For a binary endpoint it might be an event-rate difference or ratio; for a time-to-event endpoint it might be a hazard ratio; for a continuous endpoint it might be a difference in means or another prespecified contrast.
Why endpoint specification comes first
Statistical methodology follows the structure of the endpoint. A time-to-event endpoint requires explicit handling of censoring and follow-up. A binary endpoint requires a defined assessment window. A continuous endpoint requires a measurement and analysis time point. Because the registry information available here does not report the registered primary endpoints, the specific primary analysis cannot be established from the record.
Typical analysis framework for cardiovascular prevention trials
For a prevention study whose outcome is a clinical cardiovascular event, a time-to-event analysis is often appropriate because patients can experience an event at different times and some may remain event-free at the end of observation. Kaplan-Meier estimation can describe event-free survival, while a log-rank test can compare survival curves and a Cox proportional-hazards model can estimate a hazard ratio.
Those methods are presented here as the standard statistical framework for this type of endpoint, not as a claim that the registry specifies them for ALLHAT. The ClinicalTrials.gov record does not provide the corresponding posted statistical analysis.
Multiplicity
The intervention list contains several pharmacologic and behavioral interventions, but the registry information available here does not specify the formal hypothesis hierarchy, familywise error strategy, alpha allocation, or multiplicity adjustment. These details are essential when a study evaluates multiple treatment comparisons or multiple endpoints.
Missing data and censoring
The registry information available here does not specify missing-data or censoring rules. For longitudinal clinical-trial outcomes, these rules can materially affect estimates because patients may have different lengths of observation, incomplete measurements, or an event that occurs after the last observed assessment.
6. Planned Analysis
No results are posted on ClinicalTrials.gov for this record. The registry also does not provide registered primary endpoint definitions or posted statistical analyses from which an endpoint-specific result could be summarized.
How a cardiovascular prevention endpoint would typically be analysed
If the primary outcome were defined as time from randomization to a cardiovascular event or death, the usual analysis would begin with Kaplan-Meier estimates of the event-time distribution. Treatment groups could then be compared using a log-rank test, with a Cox proportional-hazards model providing a relative effect estimate such as a hazard ratio and its confidence interval.
If instead the endpoint were a binary outcome assessed over a fixed period, an analysis would typically compare event proportions between randomized groups using an appropriate risk difference, risk ratio, odds ratio, or regression model. If the endpoint were continuous, the analysis would generally compare the prespecified treatment-group means or another appropriate summary measure.
Primary analysis principle
The analysis should follow the endpoint definition and estimand specified before examining outcomes. The same clinical question can require different statistical methods depending on whether the outcome is binary, continuous, or time-to-event.
Randomization principle
For efficacy, the randomized treatment assignment is generally the foundation of the primary comparison. Departing from randomized assignment can introduce post-randomization selection into the treatment contrast.
Precision
A treatment-effect estimate should normally be accompanied by a confidence interval. The interval communicates statistical uncertainty that a point estimate alone cannot convey.
Multiplicity
When several hypotheses are tested, the interpretation of individual P-values depends on the prespecified multiplicity strategy and the relationship among the hypotheses.
7. Statistical Methods Explained
Why is randomization statistically important?
Randomization separates treatment assignment from baseline prognostic factors in expectation. This means that, before outcomes are observed, the treatment groups are formed by the allocation mechanism rather than by investigators or patients selecting the treatment associated with their characteristics. The resulting comparison provides the foundation for estimating the causal effect of assignment to the intervention.
Why would a prevention trial often use time-to-event analysis?
Cardiovascular prevention outcomes may occur at different times for different participants. A time-to-event method uses both the occurrence and timing of events and can retain information from participants who have not experienced the event by the end of their observed follow-up. Such participants are typically censored rather than treated as if they had experienced the event.
What does a hazard ratio represent?
When a Cox model is appropriate, the hazard ratio compares the modeled instantaneous event rates between treatment groups. An HR below 1 indicates a lower estimated event hazard in the numerator treatment group relative to the reference group. It is not the same as an absolute risk reduction, a probability of benefit, or a statement about every individual participant.
The ratio is a relative time-to-event measure. Its interpretation depends on the fitted model and the underlying event process, including the proportional-hazards assumption when a standard Cox model is used.
Why is a confidence interval needed?
A point estimate describes the observed treatment contrast, but it does not by itself communicate how statistically precise that estimate is. A confidence interval provides a range of parameter values compatible with the statistical model and sampling process at the stated confidence level. Wider intervals generally indicate less precision than narrower intervals.
Why does a P-value not measure treatment effect size?
A P-value measures how compatible the observed data are with a specified null hypothesis under the assumptions of the statistical test. It does not tell the reader how large or clinically important an effect is. Effect size, absolute outcomes, and confidence intervals are needed to understand magnitude and precision.
Why does multiplicity matter?
If several hypotheses are tested, the chance of obtaining at least one apparently positive result can increase when each test is interpreted independently at the same nominal significance level. A prespecified multiplicity strategy controls the interpretation of a family of hypotheses and clarifies which findings are confirmatory and which are exploratory.
8. Interpretation of the Randomized Design
The most important statistical feature explicitly identified in the registry is randomization. In a randomized trial, the treatment comparison is defined by assignment rather than by the characteristics that led an individual participant to receive a particular intervention. This distinction is especially important in cardiovascular research, where age, comorbidities, baseline blood pressure, lipid levels, diabetes, prior cardiovascular disease, and other factors can influence outcomes.
Randomization establishes a principled basis for comparing outcomes between assigned intervention groups. With adequate implementation and follow-up, differences in outcomes can be interpreted as differences associated with randomized treatment assignment rather than simply differences in baseline patient characteristics.
Randomization does not guarantee numerically identical baseline groups in every sample, eliminate missing observations, prevent treatment changes after assignment, or remove uncertainty from the estimated treatment effect. Those issues require additional design and analysis procedures.
In prevention research, the clinically meaningful question is often whether an intervention changes the occurrence of future events over a defined period. This makes event definitions, follow-up time, competing events, censoring, and the chosen estimand particularly important to the interpretation.
9. Intervention Classes and Statistical Comparisons
The registry lists both antihypertensive and lipid-lowering interventions, along with a fat-restricted diet. The presence of multiple interventions means that the statistical structure of the trial is important: the clinical question cannot be reconstructed accurately from the intervention names alone.
| Intervention listed by registry | Broad therapeutic category | Statistical consideration |
|---|---|---|
| Inhibitors, ACE | Antihypertensive | The treatment contrast would require a defined randomized comparison and endpoint. |
| Amlodipine | Antihypertensive | The treatment contrast would require a defined randomized comparison and endpoint. |
| Lisinopril | Antihypertensive | The treatment contrast would require a defined randomized comparison and endpoint. |
| Doxazosin | Antihypertensive | The treatment contrast would require a defined randomized comparison and endpoint. |
| Chlorthalidone | Antihypertensive | The treatment contrast would require a defined randomized comparison and endpoint. |
| Pravastatin | Lipid-lowering | The treatment contrast would require a defined randomized comparison and endpoint. |
| Diet, fat-restricted | Behavioral | The treatment contrast would require a defined randomized comparison and endpoint. |
The registry does not specify here how these interventions were combined into formal randomized comparisons. It therefore would be inappropriate to assign a particular drug-versus-drug or drug-versus-control contrast to the study solely from this intervention list.
10. Trial Timeline
Trial start
The ClinicalTrials.gov record lists August 1993 as the trial start date.
Randomized prevention trial
The registry classifies ALLHAT as a randomized phase 3 study with prevention as its primary purpose.
Primary completion
The registry lists March 2002 as the primary completion date.
Registry status
The current trial record identifies the study status as completed.
11. Limitations
- No registered primary endpoints reported: the ClinicalTrials.gov record represented here does not provide primary endpoint definitions or time frames.
- No posted statistical analyses: the record does not contain posted statistical analyses from which treatment-effect estimates, confidence intervals, or P-values can be summarized.
- No enrollment value reported: the registry information available here does not report a numerical enrollment value.
- Incomplete treatment structure: the intervention list identifies agents and a behavioral intervention but does not, by itself, establish the formal randomized comparison structure.
- Unspecified analysis plan: the registry information available here does not specify the primary statistical model, hypothesis-testing hierarchy, alpha allocation, or multiplicity procedure.
- Unspecified missing-data strategy: censoring, missing-data handling, and treatment-discontinuation rules are not reported in the available registry information.
- Endpoint-dependent methodology: different cardiovascular endpoints require different estimands and statistical methods. Without the registered endpoint definitions, selecting one primary analysis would require information beyond the registry record.
12. Why This Trial Matters Statistically
ALLHAT is an important statistical teaching case because its registry description brings together several central principles of clinical-trial design: randomization, prevention, multiple intervention types, cardiovascular event outcomes, and long-term follow-up. Even when numerical outcome results are not available in the registry record, the design raises the same methodological questions that determine whether a treatment comparison is statistically interpretable.
| Concept | How it applies to ALLHAT |
|---|---|
| Randomization | The registry explicitly identifies the allocation as randomized. |
| Phase 3 design | The trial is classified as Phase 3. |
| Prevention | The registry identifies prevention as the primary purpose. |
| Multiple interventions | The registry lists antihypertensive drugs, a lipid-lowering drug, and a fat-restricted diet. |
| Cardiovascular outcomes | The registry associates the study with cardiovascular diseases and several cardiovascular and metabolic conditions. |
| Endpoint specification | Primary endpoint definitions and time frames are not reported in the registry information available here. |
| Statistical analysis plan | Posted statistical analyses are not reported in the ClinicalTrials.gov record. |
| Multiplicity | The intervention list makes the formal comparison structure important, but the available registry information does not specify the multiplicity strategy. |
| Time-to-event analysis | Cardiovascular prevention endpoints are often analysed with survival methods when event timing and censoring are relevant; the registry does not specify such a method for this record. |
13. The Statistical Story of a Randomized Prevention Trial
A prevention trial can be understood as a sequence of statistical decisions. First, the population and intervention strategy are defined. Second, randomization establishes the comparison. Third, an endpoint specifies exactly what constitutes an event or outcome. Fourth, the estimand determines the quantity being compared. Finally, the statistical model estimates that quantity while accounting for follow-up, censoring, variability, and the prespecified testing framework.
Question 1: What is being prevented?
The registry title identifies prevention of heart attack as the central purpose of the trial, while the conditions field covers a broader cardiovascular disease context.
Question 2: What is being compared?
The registry identifies several interventions, but the available record does not specify the formal randomized comparison structure connecting those interventions to particular trial arms.
Question 3: What is the endpoint?
The ClinicalTrials.gov record available here does not report registered primary endpoints, so the precise primary outcome definition cannot be established from this record.
Question 4: What is the estimand?
The estimand should correspond to the prespecified clinical question—for example, a risk difference, risk ratio, mean difference, or time-to-event hazard ratio depending on the endpoint.
14. What a Complete Statistical Analysis Would Require
A full statistical analysis of a randomized prevention trial requires more than the trial title and intervention list. At minimum, the analysis must establish the target population, randomized comparison, primary endpoint, follow-up window, estimand, analysis population, missing-data rules, censoring rules, and multiplicity strategy.
| Component | Why it matters |
|---|---|
| Population | Defines to whom the treatment effect applies. |
| Randomized comparison | Defines the treatment contrast created by the allocation mechanism. |
| Primary endpoint | Defines exactly what outcome is tested. |
| Time frame | Determines the period over which the outcome is evaluated. |
| Estimand | Defines the treatment effect being targeted. |
| Analysis population | Determines which participants contribute to the primary analysis. |
| Missing-data rules | Determine how incomplete observations affect estimation. |
| Censoring rules | Determine how incomplete event-time observation contributes information. |
| Multiplicity strategy | Determines how multiple hypotheses should be interpreted while controlling statistical error. |
The ClinicalTrials.gov record supplies the trial's randomized allocation, phase, purpose, dates, sponsor, conditions, and intervention list, but the statistical elements above are not fully specified in the registry information available here.
15. Interpreting Null and Positive Findings in Prevention Trials
For a prevention trial, statistical interpretation should distinguish the existence of an observed treatment contrast from the magnitude and precision of that contrast. A P-value alone does not establish clinical importance, while a confidence interval alone does not eliminate the need to consider the endpoint's clinical meaning and prespecified testing strategy.
The point estimate is the principal numerical summary of the observed treatment contrast. Its meaning depends entirely on the endpoint and estimand—for example, a difference in event probabilities has a different interpretation from a hazard ratio.
The confidence interval describes statistical uncertainty around the estimated treatment effect under the specified analysis framework. It should be interpreted alongside the point estimate rather than as a substitute for it.
The P-value evaluates compatibility with a specified null hypothesis under the assumptions of the test. It does not quantify the size, importance, or probability of the treatment effect.
16. Randomized Trials and Causal Interpretation
Randomization is particularly valuable when interventions target chronic cardiovascular risk. Because treatment assignment is determined by the randomized design rather than by the participant's anticipated outcome, the treatment groups can be compared without requiring every potential confounding variable to be measured and modelled.
That advantage applies to the treatment assignment defined by the protocol. Events occurring after randomization, treatment discontinuation, changes in treatment, adherence, competing outcomes, and incomplete follow-up can still affect how the randomized comparison is analysed and interpreted.
17. Cardiovascular Conditions in the Registry
| Condition listed by the registry | Statistical relevance |
|---|---|
| Cardiovascular Diseases | Broad cardiovascular disease context for a prevention trial. |
| Coronary Disease | Relevant cardiovascular disease context. |
| Diabetes Mellitus | Metabolic condition associated with cardiovascular risk. |
| Heart Diseases | Broad cardiac disease context. |
| Hypercholesterolemia | Relevant to lipid-lowering intervention. |
| Hypertension | Relevant to antihypertensive intervention. |
| Myocardial Infarction | Directly related to the heart-attack prevention framing of the trial title. |
| Myocardial Ischemia | Cardiovascular disease context. |
| Heart Failure | Cardiovascular disease context and potential clinical outcome domain. |
The conditions list should not be treated as a substitute for the primary endpoint definition. A condition can describe the population or clinical context without necessarily being the event that defines the primary statistical analysis.
18. Trial Sponsorship and Study Context
Sponsorship identifies the organization recorded as the lead sponsor and does not itself determine the validity of a statistical analysis. Statistical validity depends on the trial design, prespecified analysis, data quality, endpoint definition, and appropriate interpretation of the resulting estimates.
19. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The registry establishes that ALLHAT was randomized and designed as a phase 3 prevention trial. It does not provide posted statistical analyses or registered primary endpoint results in the information available here.
Clinical interpretation
The registry frames the study around antihypertensive and lipid-lowering treatment and prevention of heart attack within a broad cardiovascular disease context. The clinical meaning of any specific treatment effect would require the corresponding endpoint and outcome results.
20. Important Statistical Questions for ALLHAT
- What was the exact primary endpoint? The registry information available here does not report it.
- What was the formal randomized comparison? The intervention list alone does not specify the complete comparison structure.
- Was the primary outcome time-to-event? The registry information available here does not establish this.
- What analysis population was prespecified? The available registry information does not specify the primary analysis population.
- How was multiplicity controlled? The available registry information does not report an alpha-allocation or multiplicity strategy.
- How were missing observations handled? The available registry information does not specify the missing-data strategy.
- How was censoring handled? The available registry information does not provide endpoint-specific censoring rules.
21. Why the Endpoint Matters More Than the Statistical Test
A common mistake in clinical-trial interpretation is to begin with a statistical test rather than the clinical estimand. The correct sequence is the reverse: define the clinical question, specify the endpoint, define the treatment contrast, and then select the statistical method that estimates the target quantity appropriately.
This sequence prevents the statistical procedure from determining the clinical question after the data have already been observed.
For ALLHAT, the registry clearly establishes the clinical context and randomized design, but the endpoint and analysis components needed to complete this sequence are not reported in the available record.
22. Sources
- ClinicalTrials.gov: NCT00000542 — Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Continue through the Clinical Biostats knowledge graph
Explore statistical concepts, clinical-trial methodology, and analysis workflows across the Clinical Biostats library.
23. Record Summary
ALLHAT is registered as a completed, randomized phase 3 prevention trial sponsored by the National Heart, Lung, and Blood Institute. Its title identifies antihypertensive and lipid-lowering treatment to prevent heart attack, while its intervention list includes ACE inhibitors, amlodipine, lisinopril, doxazosin, chlorthalidone, pravastatin, and a fat-restricted diet. The registry associates the study with a broad cardiovascular disease context and records a start date of 1993-08 and primary completion date of 2002-03.
From a statistical perspective, the defining feature is the randomized design. A complete treatment-effect analysis would additionally require the precise endpoint definitions, follow-up windows, randomized comparison structure, estimand, analysis population, and prespecified statistical methods. Those elements, along with posted numerical statistical results, are not reported in the ClinicalTrials.gov record represented here.